Crushing riluzole tablets: evaluation of loss of powder and active principle in a home-simulation experiment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Crushing riluzole tablets: evaluation of loss of powder and active principle in a home-simulation experiment

Published:2023-08-16 Issue:7-8 Volume:24 Page:634-640
ISSN:2167-8421
Container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
language:en
Short-container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Author:

Casiraghi Antonella¹^ORCID,Gentile Andrea¹^ORCID,Marjanovic Ivan²,Chiò Adriano³⁴^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, University of Milan, Milan, Italy

2. Zambon Biotech SA, Cadempino, Switzerland

3. ‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, Italy

4. Neurology 1, AOU Città della Salute e della Scienza Hospital of Turin, Turin, Italy

Funder

Zambon Biotech S.A.

Publisher

Informa UK Limited

Subject

Neurology (clinical),Neurology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678421.2023.2245860

Reference31 articles.

1. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis

2. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy

3. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study

4. Dose-ranging study of riluzole in amyotrophic lateral sclerosis

5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND);Miller RG;Cochrane Database Syst Rev,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment continuity of amyotrophic lateral sclerosis with available riluzole formulations: state of the art and current challenges in a ‘real-world’ setting;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2024-07-07

2. Continuity of treatment in ALS: Benefits and challenges of maintaining riluzole over the course of the disease;Journal of the Neurological Sciences;2024-06

3. The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe;Scientific Reports;2023-12-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3